New Narcolepsy Drug Enters Competitive Orexin Market
Pharmaceutical distributors and healthcare operators should watch how orexin's launch shifts narcolepsy formulary competition.
Updated on Nov. 2, 2026 in Healthcare
Takeda Pharmaceuticals received FDA approval for orexin, the first agonist drug approved for Type 1 narcolepsy. The approval arrives as competition in the orexin market intensifies, including Eli Lilly's roughly $6.3 billion acquisition of Centessa Pharmaceuticals in March 2026.
Why it matters
Orexin's approval opens a new treatment category for narcolepsy, a market where established players such as Harmony's Wakix now face a rival mechanism. For operators in pharmaceutical and healthcare supply chains, the combination of FDA clearance and large-scale M&A signals where capital and competitive positioning are flowing.
Eli Lilly paid roughly $6.3 billion to acquire Centessa Pharmaceuticals in March 2026, and Harmony's only approved product, Wakix, generated over $261 million in net product revenue in the second quarter of 2026, a 30% increase from the same period in 2025.
The players
Takeda Pharmaceuticals
A global pharmaceutical company with a broad portfolio spanning neuroscience, oncology, and rare diseases, which received FDA approval for orexin.
Eli Lilly
A large U.S. pharmaceutical manufacturer whose acquisition of Centessa Pharmaceuticals positions it in the orexin market.
Centessa Pharmaceuticals
A biotechnology company developing orexin-related therapies, acquired by Eli Lilly in March 2026 for roughly $6.3 billion.
Harmony Biosciences
A specialty pharmaceutical company whose only approved product, Wakix, treats narcolepsy and reported strong second-quarter 2026 revenue growth.
Alkermes
A biopharmaceutical company running a global Phase 3 program evaluating alixorexton in Type 1 and Type 2 narcolepsy.
The details
Orexins are neuropeptides secreted by neurons in the hypothalamus, and orexin agonists work by boosting them. Clinical data from narcolepsy trials showed that this boost minimizes excessive sleepiness. Alkermes has begun a global Phase 3 program for alixorexton across Type 1 and Type 2 narcolepsy, and early clinical data showed it was significantly more effective than placebo at keeping Type 2 patients awake.
Timeline
March 2026: Eli Lilly acquires Centessa Pharmaceuticals for roughly $6.3 billion.
Second quarter 2026: Wakix reports over $261 million in net product revenue.
Market Landscape
Orexin's FDA approval places a new mechanism alongside Harmony's Wakix, which generated over $261 million in second-quarter 2026 net product revenue. Eli Lilly's $6.3 billion purchase of Centessa signals that large pharmaceutical companies are competing to secure positions in the orexin category.
Operators in pharmaceutical distribution, specialty pharmacy, and healthcare payer contracting should monitor how orexin's launch affects formulary positioning for narcolepsy drugs. Businesses tracking competitor strategy should note that large acquisitions like Eli Lilly's are reshaping which companies control this therapeutic category.
The takeaway
Watch for Takeda's orexin launch metrics and Alkermes' Phase 3 readouts as indicators of how quickly the category will expand. Healthcare operators should track formulary decisions for narcolepsy therapies as new mechanisms reach the market.
Further reading
For broader context on drug development and approvals, explore more Healthcare coverage.
Source note: This article includes information reported by Labroots.
